Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease

被引：0
|
作者：
Andrew J. Leidner
Harrell W. Chesson
Philip R. Spradling
Scott D. Holmberg
机构：
[1] Centers for Disease Control and Prevention,Division of Viral Hepatitis
[2] Centers for Disease Control and Prevention,Division of Sexually Transmitted Disease Prevention
来源：
Applied Health Economics and Health Policy | 2017年 / 15卷
关键词：
Supplemental Appendix; Background Mortality; Moderate Fibrosis; Early Stage Liver Disease; Increase Background Mortality;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：65 / 74
页数：9
相关论文
共 41 条
  • [21] COST-EFFECTIVENESS OF NON-INVASIVE LIVER FIBROSIS TESTS FOR TREATMENT DECISIONS IN PATIENTS WITH CHRONIC HEPATITIS C: SYSTEMATIC REVIEW AND ECONOMIC EVALUATION
    Tsochatzis, E.
    Crossan, C.
    Longworth, L.
    Gurusamy, K.
    Rodriguez-Peralvarez, M.
    Mantzoukis, K.
    O'Brien, J.
    Thalassinos, E.
    Papastergiou, V.
    Noel-Storr, A.
    Davidson, B.
    Burroughs, A.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S33 - S33
  • [22] Treatment of hepatitis C (HCV) in prison settings is cost-effective: Mathematical modeling of epidemiology, disease outcomes and cost-effectiveness
    Watson, Katrina
    Watson, Donald
    Scuffham, Paul
    Bell, Sally
    Desmond, Paul
    Tuck, Eugenie
    Lightfoot, Tim
    Pruscino, Michael
    Greene, David
    McNeill, Helen
    Richmond, Jacqui
    Karvelas, Maria
    HEPATOLOGY, 2006, 44 (04) : 286A - 286A
  • [23] Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson's disease patients
    Pahwa, R.
    Garrison, L.
    Zimmerman, M.
    Johnson, R.
    Nguyen, J.
    Li, M.
    Patni, R.
    MOVEMENT DISORDERS, 2018, 33 : S398 - S398
  • [24] Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies
    Hayley Bennett
    Jason Gordon
    Beverley Jones
    Thomas Ward
    Samantha Webster
    Anupama Kalsekar
    Yong Yuan
    Michael Brenner
    Phil McEwan
    The European Journal of Health Economics, 2017, 18 : 1001 - 1011
  • [25] Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies
    Bennett, Hayley
    Gordon, Jason
    Jones, Beverley
    Ward, Thomas
    Webster, Samantha
    Kalsekar, Anupama
    Yuan, Yong
    Brenner, Michael
    McEwan, Phil
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2017, 18 (08): : 1001 - 1011
  • [26] Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison
    Babigumira, Joseph B.
    Karichu, James K.
    Clark, Samantha
    Cheng, Mindy M.
    Garrison, Louis P.
    Maniecki, Maciej B.
    Hamid, Saeed S.
    BMJ OPEN, 2023, 13 (05):
  • [27] Pre-transplant sofosbuvir and ribavirin for patients with advanced liver disease and chronic hepatitis C awaiting deceased donor liver transplantation: A cost-effectiveness analysis
    Wright, Alissa J.
    Kim, Arthur Y.
    Fishman, Jay A.
    Linas, Benjamin P.
    Chung, Raymond T.
    HEPATOLOGY, 2014, 60 : 1045A - 1045A
  • [28] Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma
    Salazar, James
    Saxena, Varun
    Kahn, James G.
    Roberts, John P.
    Mehta, Neil
    Volk, Michael
    Lai, Jennifer C.
    TRANSPLANTATION, 2017, 101 (05) : 1001 - 1008
  • [29] ASSESSING THE IMPORTANCE OF FIBROSIS STAGE ON THE COST-EFFECTIVENESS OF BIRTH-COHORT VERSUS RISK-BASED SCREENING AND TREATMENT FOR HEPATITIS C VIRUS INFECTION
    McEwan, P.
    Ward, T.
    Yuan, Y.
    L'Italien, G.
    VALUE IN HEALTH, 2013, 16 (03) : A186 - A187
  • [30] Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis
    Buti, Maria
    Dominguez-Hernandez, Raquel
    Oyaguez, Itziar
    Angel Casado, Miguel
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2016, 39 (07): : 449 - 457
12345